 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Efficacy of Cabozantinib in the Treatment of Metastatic Renal Cell Carcinoma: An Analysis of CABOREAL Results from Real-World Research

Eur J Cancer: Efficacy of Cabozantinib in the Treatment of Metastatic Renal Cell Carcinoma: An Analysis of CABOREAL Results from Real-World Research

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

zyprexa 5 mg

meloxicam 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Renal cell carcinoma (RCC) is the most common kidney cancer, accounting for 5% of all adult male malignancies, 3% of female malignancies, and approximately 80% of all kidney cancers
.

Many patients with renal cell carcinoma remain asymptomatic until the advanced stage of the disease, and 25-30% of them have metastases at the time of diagnosis

Renal cell carcinoma (RCC) is the most common kidney cancer, accounting for 5% of all adult male malignancies, 3% of female malignancies, and approximately 80% of all kidney cancers

This multicenter (n=26), observational, retrospective study included patients with mRCC who received ≥1 dose of cabozantinib
.

The kaplan meier method was used to estimate the overall survival (OS); the log-rank test was used to compare the subgroups

This multicenter (n=26), observational, retrospective study included patients with mRCC who received ≥1 dose of cabozantinib

A total of 410 mRCC patients (74% males and 26% females) were included in the study

More than half of the patients (57.

Cabozantinib Therapeutic Dosage Model

At the end of the follow-up period, most patients (85.
1%) permanently discontinued cabozantinib treatment, mainly due to disease progression (54.
9%) or AEs (24.
9%)
.

About half of the patients (54.

At the end of the follow-up period, most patients (85.

The total median follow-up time was 14.

The median OS of elderly patients (>75 years old) was not significantly different from that of younger patients (13.
3 months vs 14.
6 months, p=0.
3200)
.

The IMDC low-risk and moderate-risk groups had a longer median OS than the IMDC poor-risk group (not reached, 17.

The median OS of elderly patients (>75 years old) was not significantly different from that of younger patients (13.

OS subgroup analysis

Multivariate analysis showed that longer survival time was related to the following factors: body mass index (BMI) ≥ 25kg/m ² (compared with BMI 18.
5-25kg/m ² , HR = 0.
64; 95% CI: 0.
48-0.
85, p =0.
0021); previous nephrectomy (HR=0.
64; 95% CI: 0.
45-0.
90, p=0.
0109); and IMDC low risk (HR=0.
15; 95% CI: 0.
08-0.
29, p<0.
0001) or IMDC The degree risk (HR=0.
38; 95%CI: 0.
28-0.
53, p<0.
0001) was compared with the IMDC bad risk
.

The shorter survival period was associated with not taking a full dose of cabozantinib at the beginning of treatment (40/20 mg vs 60 mg, HR=1.
35; 95% CI: 1.
00-1.
82, p=0.
0486)
.

Multivariate analysis

In summary, this largest real-world data shows that Cabozantinib is effective for patients with metastatic renal cell carcinoma who have not selected previous treatments
.
And the initial full dose (60 mg/day) can improve the prognosis of patients
.
This largest real-world data shows that Cabozantinib is effective for patients with metastatic renal cell carcinoma who have not selected previous treatments
.
And the initial full dose (60 mg/day) can improve the prognosis of patients
.
This largest real-world data shows that Cabozantinib is effective for patients with metastatic renal cell carcinoma who have not selected previous treatments
.
And the initial full dose (60 mg/day) can improve the prognosis of patients
.

Original source:

Albiges L, Fléchon A, Chevreau C, Topart D, Gravis G, Oudard S, Tourani JM, Geoffrois L, Meriaux E, Thiery-Vuillemin A, Barthélémy P, Ladoire S, Laguerre B, Perrot V, Billard A, Escudier B, Gross-Goupil M.
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Eur J Cancer.
2021 Jan;142:102-111.
doi: 10.
1016/j.
ejca.
2020.
09.
030.
Epub 2020 Nov 27.
PMID: 33253997.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.